Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (First Line) | Decision Base | US | 2015

What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies?

The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming increasingly crowded. In recent years, several new, high-priced therapies have been approved for use in this patient population, making this lucrative market more dynamic and competitive. The launch of ibrutinib (Johnson & Johnson/Janssen/Pharmacyclics’ Imbruvica) and idelalisib (Gilead Sciences’ Zydelig) in 2014 transformed the treatment algorithm and improved the outlook for patients. Nevertheless, clinical and commercial opportunity awaits emerging therapies that can provide greater survival benefits than the current standards of care and add minimal toxicities to the existing chemotherapy regimens used to treat first-line CLL/SLL.

Contact sales account_box

Hodgkin’s Lymphoma US 2015

Report

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…

north_east

Report

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…

north_east

Report

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…

north_east

Report

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…

north_east

Report

Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

north_east

Product logins

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (First Line) | Decision Base | US | 2015

Related Market Assessment Reports

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer

Follow us

Contact us